Taiho Ventures

What they do

Taiho Ventures, LLC was established in 2016 as the strategic corporate venture capital arm of Taiho Pharmaceutical Co., Ltd., a Japanese specialty pharmaceutical company and subsidiary of Otsuka Holdings. Positioned at the intersection of global biotech innovation and corporate R&D, the firm seeks to invest in promising start-ups conducting first-in-class drug discovery. What makes Taiho Ventures distinctive is its deep domain expertise in oncology and its ability to provide portfolio companies with strategic guidance for the Japanese and Asian markets. The firm is highly regarded in the life sciences ecosystem for its stable, long-term investment strategy, often stepping up to lead or co-lead rounds even during broader market downturns in early-stage oncology investing.

What they look for

Taiho Ventures aims to create significant value by investing in the global biotech venture community and providing innovative science for its parent company, Taiho Pharmaceutical. Their core thesis revolves around backing early-stage companies with first-in-class or new biology-based approaches to drug discovery, as well as innovative platform technologies.

Stage

Pre-seed, Seed, Series A, Series B+

Sectors

Healthcare, Deeptech

Based

Menlo Park, US